<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>7748712</identifier>
<setSpec>1130-0108</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Casado, M</dc:author>
<dc:author>Aguirre, A</dc:author>
<dc:author>González-Asanza, C</dc:author>
<dc:author>Pérez-Roldán, F</dc:author>
<dc:author>Clemente, G</dc:author>
<dc:author>Alvarez, E</dc:author>
<dc:author>Bañares, R</dc:author>
<dc:description xml:lang="en">We report the case of a 68-year-old male HVC+ diagnosed as cholestatic hepatitis induced by glybenclamide, following a non-insulin dependent diabetes mellitus treatment. When the drug was discontinued normal analytic parameters were obtained. However, HVC may induce more cholestatic and cytolysic changes on the hepatitis due to glybenclamide. When reviewing the literature only one similar case has been previously reported, although several disturbances in liver function tests have been described in other reports. Routine biochemical tests including liver function are indicated in patients receiving antidiabetic agents in order to make an early diagnosis of liver toxicity.</dc:description>
<dc:type>Case Reports</dc:type>
<dc:language>es</dc:language>
<dc:date>1995 Feb </dc:date>
<dc:title xml:lang="es">Hepatitis colestática por glibenclamida en paciente con virus de hepatitis C.</dc:title>
<dc:title xml:lang="en">[Cholestatic hepatitis caused by glybenclamide in a patient with hepatitis C virus].</dc:title>
<dc:publisher>Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva</dc:publisher>
</metadata>
</record>
</pubmed-document>
